Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Regen BioPharma (RGBP) Short term Debt (2016 - 2024)

Regen BioPharma (RGBP) has disclosed Short term Debt for 9 consecutive years, with $800149.0 as the latest value for Q2 2024.

  • On a quarterly basis, Short term Debt rose 300.07% to $800149.0 in Q2 2024 year-over-year; TTM through Jun 2024 was $800149.0, a 300.07% increase, with the full-year FY2023 number at $200000.0, down 72.92% from a year prior.
  • Short term Debt was $800149.0 for Q2 2024 at Regen BioPharma, up from $400000.0 in the prior quarter.
  • In the past five years, Short term Debt ranged from a high of $800149.0 in Q2 2024 to a low of $3048.0 in Q4 2021.
  • A 5-year average of $297704.7 and a median of $200000.0 in 2021 define the central range for Short term Debt.
  • Peak YoY movement for Short term Debt: tumbled 92.59% in 2021, then skyrocketed 7867.65% in 2022.
  • Regen BioPharma's Short term Debt stood at $40000.0 in 2020, then tumbled by 92.38% to $3048.0 in 2021, then soared by 5956.92% to $184615.0 in 2022, then soared by 333.33% to $800000.0 in 2023, then rose by 0.02% to $800149.0 in 2024.
  • Per Business Quant, the three most recent readings for RGBP's Short term Debt are $800149.0 (Q2 2024), $400000.0 (Q1 2024), and $800000.0 (Q4 2023).